Search
User Avatar Login
The Defender
  • Explore The Defender
  • Categories
    • CHD.TV
  • Explore CHD.TV
  • Archive
    • Resources
  • Explore Our Resources
  • CHD Bookstore
  • CHD Films
  • eBooks
    • Community
  • Explore Advocacy
  • Community
  • Advocacy Help
    • Science
  • Explore the Science Section
  • Science Library
  • Vaccines
  • Electromagnetic Radiation
    • Legal Justice
  • Explore Litigation
  • Learn The Law
    • About Us
  • About Children’s Health Defense
  • More from CHD
    • Vax-Unvax: Let The Science Speak Home › Citations

    Chapter 3

    This is a listing of all citations in this chapter.

    61

    Carolyn M. Gallagher and Melody S. Goodman. “Hepatitis B Vaccination of Male Neonates and Autism Diagnosis, NHIS 1997-2002,” Journal of Toxicology and Environmental Health Part A 73, no. 24 (2010): 1665-167, doi:10.1080/15287394.2010.519317.

    62

    Carolyn M. Gallagher and Melody S. Goodman. “Hepatitis B Vaccination of Male Neonates and Autism Diagnosis, NHIS 1997-2002,” Journal of Toxicology and Environmental Health Part A 73, no. 24 (2010): 1665-167, doi:10.1080/15287394.2010.519317.

    63

    Carolyn M. Gallagher and Melody S. Goodman, “Hepatitis B Triple Series Vaccine and Developmental Disability in US Children Aged 1-9 Years,” Toxicology and Environmental Chemistry 90, no. 5 (2008): 997-1008, doi:10.1080/02772240701806501.

    64

    Carolyn M. Gallagher and Melody S. Goodman, “Hepatitis B Triple Series Vaccine and Developmental Disability in US Children Aged 1-9 Years,” Toxicology and Environmental Chemistry 90, no. 5 (2008): 997-1008, doi:10.1080/02772240701806501.

    65

    Carolyn M. Gallagher and Melody S. Goodman, “Hepatitis B Triple Series Vaccine and Developmental Disability in US Children Aged 1-9 Years,” Toxicology and Environmental Chemistry 90, no. 5 (2008): 997-1008, doi:10.1080/02772240701806501.

    66

    Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

    67

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    68

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    69

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    70

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    71

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    72

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    73

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    74

    John P. Barile et al., “Thimerosal Exposure in Early Life and Neuropsychological Outcomes 7-10 Years Later,” Journal of Pediatric Psychology 37, no. 1 (2012): 106-118. doi:10.1093/jpepsy/jsr048.

    75

    Nick Andrews et al., “Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association,” Pediatrics 114, no. 3 (2004): 584–591, doi:10.1542/peds.2003-1177-L.

    76

    Nick Andrews et al., “Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association,” Pediatrics 114, no. 3 (2004): 584–591, doi:10.1542/peds.2003-1177-L.

    77

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    78

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    79

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    80

    Nick Andrews et al., “Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association,” Pediatrics 114, no. 3 (2004): 584–591, doi:10.1542/peds.2003-1177-L.

    81

    Nick Andrews et al., “Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association,” Pediatrics 114, no. 3 (2004): 584–591, doi:10.1542/peds.2003-1177-L.

    82

    Nick Andrews et al., “Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association,” Pediatrics 114, no. 3 (2004): 584–591, doi:10.1542/peds.2003-1177-L.

    83

    Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

    84

    Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

    85

    Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

    86

    US Food and Drug Administration, FLUVIRIN®: Package Insert, 2007-2018 formulation (Summit, NJ: Seqirus, Inc., updated 2017.

    87

    Centers for Disease Control and Prevention, “Seasonal Influenza Vaccine Supply for the U.S. 2022-2023 Influenza Season,” accessed on April 13, 2023.

    88

    Pan American Health Organization, “Health in the Minamata Convention on Mercury,” accessed on April 13, 2023.

    89

    Carolyn M. Gallagher and Melody S. Goodman. 2010. “Hepatitis B Vaccination of Male Neonates and Autism Diagnosis, NHIS 1997-2002,” Journal of Toxicology and Environmental Health Part A 73, no. 24 (2010): 1665-167, doi:10.1080/15287394.2010.519317.

    90

    David A. Geier, Janet K. Kern and Mark R. Geier, “Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink,” Toxics 6, no. 4 (2018): 67, doi:10.3390/toxics6040067.